Related Experiment Video

Updated: Jun 22, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Perindopril decreases P wave dispersion in patients with stage 1 hypertension

Beste Ozben1, Mutlu Sumerkan, Azra Meryem Tanrikulu

  • 1Department of Cardiology, Marmara University Faculty of Medicine, Istanbul, Turkey. bestes@doctor.com

Journal of the Renin-Angiotensin-Aldosterone System : JRAAS
|June 9, 2009
PubMed

Insights

Perindopril significantly reduced P wave dispersion (PWD) in hypertensive patients, indicating improved atrial electrical activity. This suggests ACE inhibitors may help prevent atrial fibrillation by targeting key electrocardiographic markers.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Angiotensin-converting enzyme inhibitors (ACEIs) are known to prevent atrial fibrillation (AF) by managing blood pressure and improving atrial remodeling.
  • Increased P wave dispersion (PWD) serves as a non-invasive electrocardiographic marker for paroxysmal atrial fibrillation.

Purpose of the Study:

  • To evaluate the impact of perindopril, an ACEI, on P wave dispersion (PWD) in patients with hypertension.

Main Methods:

  • Forty-eight hypertensive patients were enrolled.
  • Blood pressure and 12-lead electrocardiograms were recorded at baseline and at multiple time points up to six months during perindopril treatment.
  • P wave dispersion was calculated as the difference between maximum and minimum P wave durations.

Main Results:

  • Perindopril treatment significantly shortened PWD at one, three, and six months compared to baseline and one-week measurements (p<0.001).
  • Baseline PWD correlated with body mass index, and six-month PWD correlated with left atrial volume index.
  • Multiple linear regression indicated that six-month PWD was related to baseline PWD.

Conclusions:

  • Perindopril treatment demonstrated a significant reduction in P wave dispersion among hypertensive patients.
  • These findings suggest perindopril's potential role in mitigating atrial electrical abnormalities associated with hypertension.
Abstract

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antihypertensive Drugs: Types of &#946;-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...